ANI Pharmaceuticals, Inc. (ANIP) Ownership
ANIP ownership summary
as of October 18, 2026- Institutions
- 107.1% of shares outstanding
- Insiders
- 5.42% of shares outstanding
- Shares outstanding
- 23.0M
- Float
- 19.7M shares available to trade
- Short interest
- 18.52% 3.5M shares short
- Days to cover
- 8.36 short interest up 40.2% vs prior month
- Institutions 107.08%
- Insiders 5.42%
ANIP top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 12.88% | 3.0M | $213.9M | +211,154 (+7.7%) | June 30, 2026 |
| 2 | Soleus Capital Management, L.P. | 3.78% | 868K | $62.7M | +47,517 (+5.8%) | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 3.65% | 838K | $60.6M | +15,160 (+1.8%) | June 30, 2026 |
| 4 | State Street Corp | 3.62% | 832K | $60.1M | +60,060 (+7.8%) | June 30, 2026 |
| 5 | TANG CAPITAL MANAGEMENT LLC | 3.08% | 708K | $51.1M | — | June 30, 2026 |
| 6 | Dimensional Fund Advisors, Inc. | 2.71% | 623K | $45.1M | +92,273 (+17.4%) | June 30, 2026 |
| 7 | American Century Companies Inc | 2.50% | 574K | $41.5M | +382,898 (+199.9%) | June 30, 2026 |
| 8 | Arrowstreet Capital Limited Partnership | 2.45% | 562K | $40.6M | −2,344 (−0.4%) | June 30, 2026 |
| 9 | Global Alpha Capital Management Ltd. | 2.43% | 558K | $40.3M | +196,763 (+54.5%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 2.34% | 536K | $38.8M | +47,206 (+9.6%) | June 30, 2026 |
| 11 | Millennium Management LLC | 2.21% | 507K | $36.7M | −84,806 (−14.3%) | June 30, 2026 |
| 12 | Nuveen, LLC | 1.81% | 415K | $30.0M | +12,667 (+3.1%) | June 30, 2026 |
| 13 | Vanguard Portfolio Management, LLC | 1.77% | 407K | $29.4M | +31,316 (+8.3%) | June 30, 2026 |
| 14 | Ranger Investment Management LP | 1.49% | 343K | $24.8M | −16,933 (−4.7%) | June 30, 2026 |
| 15 | Deutsche Bank AG | 1.41% | 323K | $23.4M | +3,768 (+1.2%) | June 30, 2026 |
| 16 | Amvescap Plc. | 1.35% | 309K | $22.4M | −15,116 (−4.7%) | June 30, 2026 |
| 17 | UBS Group AG | 1.30% | 298K | $21.5M | −200,163 (−40.2%) | June 30, 2026 |
| 18 | Kennedy Capital Management Inc | 1.29% | 296K | $21.4M | +1,942 (+0.7%) | June 30, 2026 |
| 19 | Ameriprise Financial Inc | 1.25% | 287K | $20.8M | +17,120 (+6.3%) | June 30, 2026 |
| 20 | Delaware Management Holdings Inc | 1.25% | 287K | $20.8M | −357 (−0.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 1.1M shares and 6 cut 320K.
ANIP top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | iShares Core S&P Small-Cap ETF | 5.22% | 1.2M | $86.6M | +306 (+0.0%) | September 30, 2026 |
| 2 | Avantis US Small Cap Value ETF | 3.24% | 744K | $53.8M | +1,896 (+0.3%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 2.68% | 615K | $44.4M | — | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 2.31% | 530K | $38.3M | −6,080 (−1.1%) | September 30, 2026 |
| 5 | CC&L Global Alpha - Series A | 1.22% | 279K | $20.2M | +6,689 (+2.5%) | July 31, 2026 |
| 6 | Oberweis Micro-Cap | 1.12% | 256K | $18.5M | +43,800 (+20.6%) | June 30, 2026 |
| 7 | Invesco Pharmaceuticals ETF | 1.03% | 236K | $17.1M | +523 (+0.2%) | September 30, 2026 |
| 8 | Fidelity Small Cap Index | 0.98% | 224K | $16.2M | +2,033 (+0.9%) | July 31, 2026 |
| 9 | CREF Total Global Stock Account R3 | 0.96% | 220K | $15.9M | +15,539 (+7.6%) | August 31, 2026 |
| 10 | iShares Russell 2000 Growth ETF | 0.83% | 191K | $13.8M | −242 (−0.1%) | September 30, 2026 |
| 11 | iShares S&P Small-Cap 600 Growth ETF | 0.81% | 187K | $13.5M | — | September 30, 2026 |
| 12 | State Street SPDR Port S&P 600 Sm CpETF | 0.80% | 185K | $13.4M | — | September 30, 2026 |
| 13 | State Street® SPDR® S&P® PhrmctlsETF | 0.64% | 147K | $10.6M | −1,830 (−1.2%) | September 30, 2026 |
| 14 | abrdn US Small Cap Equity Inst Svc | 0.58% | 134K | $9.7M | — | August 31, 2026 |
| 15 | abrdn-Nrth American Sml Comp I Acc USD | 0.55% | 125K | $9.1M | −755 (−0.6%) | August 31, 2026 |
| 16 | MEDICAL BioHealth EUR Acc | 0.52% | 120K | $8.7M | +32,029 (+36.5%) | August 31, 2026 |
| 17 | Vanguard Russell 2000 ETF | 0.52% | 119K | $8.6M | +1,412 (+1.2%) | September 30, 2026 |
| 18 | State Street® SPDR® S&P 600™ Sm Cp GrETF | 0.51% | 116K | $8.4M | — | September 30, 2026 |
| 19 | Vanguard Tax-Managed Small Cap Adm | 0.49% | 114K | $8.2M | — | September 30, 2026 |
| 20 | DWS Small Cap Core S | 0.48% | 110K | $8.0M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ANIP insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-13 | Meredith Cook | Sell | $77.95 | 500 | $38,975 |
| 2026-03-13 | Meredith Cook | Sell | $72.62 | 500 | $36,310 |
| 2026-03-13 | Christopher Mutz | Sell | $71.64 | 3,162 | $226,526 |
| 2026-03-11 | Thomas Andrew Rowland | Sell | $74.91 | 4,772 | $357,471 |
| 2026-03-05 | Stephen P Carey | Sell | $75.50 | 7,312 | $552,056 |
| 2026-03-03 | Ori Gutwerg | Sell | $76.50 | 2,060 | $157,590 |
| 2026-03-02 | Christopher Mutz | Sell | $74.00 | 417 | $30,858 |
| 2026-02-20 | Christopher Mutz | Sell | $78.02 | 5,323 | $415,300 |
| 2026-02-20 | Krista Davis | Sell | $77.99 | 1,730 | $134,923 |
| 2026-02-19 | Krista Davis | Sell | $77.53 | 2,084 | $161,573 |
| 2026-01-13 | Meredith Cook | Sell | $84.33 | 500 | $42,165 |
| 2025-12-18 | Krista Davis | Sell | $82.40 | 1,622 | $133,653 |
| 2025-12-12 | Meredith Cook | Sell | $82.32 | 400 | $32,928 |
| 2025-12-05 | Renee P Tannenbaum | Sell | $81.15 | 1,800 | $146,070 |
| 2025-11-13 | Chad Gassert | Sell | $88.00 | 94 | $8,272 |
| 2025-11-13 | Meredith Cook | Sell | $87.27 | 400 | $34,908 |
| 2025-11-13 | Patrick D Walsh | Sell | $86.88 | 8,643 | $750,904 |
| 2025-11-12 | Chad Gassert | Sell | $89.07 | 14,642 | $1.3M |
| 2025-10-13 | Meredith Cook | Sell | $90.09 | 400 | $36,036 |
| 2025-09-19 | Krista Davis | Sell | $98.04 | 1,000 | $98,040 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ANIP shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ANIP
Institutional investors own 107.1% of ANI Pharmaceuticals's shares and insiders 5.42%. The largest holder is BlackRock Inc with 12.88% of the shares (3.0M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 6 reduced their stake in the latest filings. Short interest is 18.52% of the float, or 8.36 days of average trading volume. The share count rose 85.0% since 2014.
Related: ANIP analyst forecast, ANIP key metrics. See the ANIP stock overview for the latest quote and news.
ANIP ownership FAQ
Who owns the most ANI Pharmaceuticals stock?
The largest shareholders of ANI Pharmaceuticals are BlackRock Inc (12.88%), Soleus Capital Management, L.P. (3.78%), Vanguard Capital Management, LLC (3.65%), State Street Corp (3.62%), TANG CAPITAL MANAGEMENT LLC (3.08%).
What percentage of ANI Pharmaceuticals is owned by institutions?
Institutions hold 107.1% of ANI Pharmaceuticals's shares outstanding; insiders hold 5.42%.
Which funds own ANI Pharmaceuticals?
The largest fund holders of ANI Pharmaceuticals are iShares Core S&P Small-Cap ETF (5.22%), Avantis US Small Cap Value ETF (3.24%), Vanguard MStar Total Stk Mkt Idx Invest (2.68%), iShares Russell 2000 ETF (2.31%), CC&L Global Alpha - Series A (1.22%).
What is ANI Pharmaceuticals's short interest?
3.5M shares of ANI Pharmaceuticals were sold short, 18.52% of the float; at the average daily volume it would take 8.36 days to cover.
Are insiders buying or selling ANI Pharmaceuticals?
Of the latest 20 reported insider transactions in ANI Pharmaceuticals (since September 19, 2025), 0 were purchases and 20 were sales.
How many shares of ANI Pharmaceuticals are outstanding?
ANI Pharmaceuticals has 23.0M shares outstanding, of which 19.7M are in the public float.